Skip to main content
OpenTrials
Completed

NCT Number: NCT00756275

Varenicline and Motivational Advice for Smokers With Substance Use Disorders

The purpose of this study is to evaluate the effects of 12 weeks of varenicline as compared to nicotine replacement therapy for smoking cessation among outpatients in treatment for substance use disorders. The intervention also incorporates counseling (Brief Advice), (adapted for sobriety settings), skills training and medication management.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Brown University, Center for Alcohol and Addiction Studies

Providence, Rhode Island, 02903, United States

About this study

People with substance use disorders (SUD) have a high prevalence and rate of smoking with little success in quitting, so stronger approaches are needed to encourage attempts to quit smoking. Brief advice (BA), to motivate cessation, produced some benefit but low abstinence rates for smokers with SUDs while adding free transdermal nicotine replacement therapy (NRT) improved short-term cessation rates. Varenicline has been found to produce higher rates of short and long-term abstinence than bupropion or placebo. However, a comparison between the efficacy of varenicline and NRT has not yet conducted with people with SUDs. Given the lack of effectiveness for standard smoking treatments for this population, what needs to be known is whether varenicline would increase the smoking abstinence rates relative to NRT when all receive motivational counseling.

The primary aim of this study is to evaluate the effects of 12 weeks of varenicline as compared to NRT, using a two-group randomized placebo-controlled design on smoking cessation rates for 12 months among 274 outpatients in treatment for SUD. The counseling incorporates BA (adapted slightly for sobriety settings by directly addressing barriers and concerns expressed by substance abusers), skills training and medication management. Confirmed point-prevalence and sustained abstinence will be assessed at 3 and 6 a months after the start of treatment. Secondary aims will examine potential mediators of effect including within-treatment abstinence, craving, and nicotine withdrawal levels.

The potential significance is to add to knowledge about the most effective ways to maximize smoking cessation among substance abusers, important given that no methods are known to work with this difficult population. No study published to date has compared varenicline to NRT for efficacy with patients with SUD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of substance abuse or dependence by DSM-IV criteria
  • Currently smoking at least 10 cigarettes per day for the past 6 months

Exclusion criteria

  • Active psychosis or marked organic impairment according to medical records, or evidence of hallucinations or delusions
  • Current use of any nicotine replacement, or other smoking cessation treatment
  • Medical contraindications for NRT (including pregnancy, nursing, women not using birth control during heterosexual sex, history of unstable angina, history of severe congestive heart failure, uncontrolled hypertension, lung cancer, supplemental oxygen, allergy to adhesive, severe skin disease that requires treatment)
  • Medical contraindications for VAR (including pregnancy, nursing, severe renal impairment by laboratory test, history of intolerance of varenicline, history of serious suicidal ideation or attempts in the past 5 years)

Treatment and study plan

Nicotine Replacement Treatment (NRT)

Drug

Nicotine replacement treatment (NRT) will follow the clinical practice guidelines for nicotine patch for people smoking at least 10 cigarettes per day (USDHHS, 2000), modified to allow 12 weeks use (tapering recommended for people with AUDs by Hughes et al., 2003b): 21 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks.

Other names: Nicotine replacement therapy, Nicotine replacement treatment, NRT

Varenicline

Drug

Varenicline (VAR, 2 mg/d in divided doses) will be administered as follows. VAR: participant takes 0.5 mg/d for the first 3 days, 1 mg/d (0.5 mg 2x/d) for the next 4 days, and 2mg/d (1.0mg 2x/d) for 12 weeks.

Other names: VAR, Chantix

Behavioral counseling for smoking cessation

Behavioral

The counseling consists of 10 sessions of Brief Advice (BA).BA is a simple smoking cessation counseling strategy: Assess smoking and initial interest in cessation, advise patient to quit smoking, assist patient in quitting, discussion of sobriety specific concerns, and cognitive-behavioral skills training. Medication management is conducted in every session, smoking cessation pamphlets are available. Session 1 (60 min, in-person) will be 1 week before Quit Day.Session 2 (30 min, in-person) takes place on Quit Day. Session 3 (10 min, in-person) will be 1 week later. Sessions 4-10 will be 5-10 min. telephone contacts at Weeks 2, 3, 4, 6, 8, 10, and 12 after Quit Day.

Other names: Behavioral treatment for smoking cessation, Behavioral counseling for quitting, Behavioral treatment for quitting

Primary outcomes

  1. 7-day Point-prevalence Smoking Abstinence

    Time frame: 3 month follow up

    7 -day smoking cessation confirmed by expired alveolar CO levels of < 10 ppm or salivary cotinine < 16 ng/ml.

  2. 7-day Point-prevalence Smoking Abstinence

    Time frame: 6 month follow up

    7 -day smoking cessation confirmed by expired alveolar CO levels of < 10 ppm or salivary cotinine < 16 ng/ml.

Secondary outcomes

  1. Length of Longest Continuous Abstinence

    Time frame: Weeks 9 to 12

  2. Percent Smoking Days

    Time frame: 3 month follow up

  3. Percent Smoking Days

    Time frame: 6 month follow up

  4. Percent Relapsed to Drug Use

    Time frame: 3 month follow up

  5. Percent Relapsed to Drug Use

    Time frame: 6 month follow up

  6. Percent Relapsed to Any Heavy Drinking

    Time frame: 3 month follow up

    6 or more drinks for men; 5 or more drinks for women

  7. Percent Relapsed to Any Heavy Drinking

    Time frame: 6 month follow up

    6 or more drinks for men; 5 or more drinks for women

  8. Beck Depression Inventory

    Time frame: Week 12

    0-10 = These ups and downs are considered normal 11-16 = Mild mood disturbance 17-20 = Borderline clinical depression 21-30 = Moderate depression 31-40 = Severe depression over 40 = Extreme depression

Sponsors and collaborators

Lead sponsor

Brown University

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

Varenicline and Motivational Advice for Smokers With SUD

Acronym: VARSUD

Important dates

Study start
2009
Primary completion
2014
Study completion
2014
First posted
Sep 22, 2008
Registry last updated
Aug 27, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.